# Moderna announces first participant dosed in Phase 3 study of mRNA-1083, a combination vaccine against influenza and COVID-19
**FDA Update**

**2023-10-24 11:24**

**https://www.ainvest.com/news/moderna-announces-first-participant-dosed-in-phase-3-study-of-mrna-1083-a-combination-vaccine-against-influenza-and-covid-19-23101000e2810aa4cfb6076a/**

Moderna announces first participant dosed in Phase 3 study of mRNA-1083, a combination vaccine against influenza and COVID-19